Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Mory Nouriani, Afshin Bahador, Jonathan S. Berek, Joan P. Cheng, Dennis S. Chi, William Arthur Cliby, Giuseppe Del Priore, Mark K. Dodson, Bridgette D. Duggan, David M. Gershenson, Scott E. Lentz, Richard T. Penson, William R. Robinson, Mildred Rodriguez, Lynda D. Roman, Mimi C. Yu, Karen Zempolich, Louis Dubeau

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

Original languageEnglish (US)
Pages (from-to)2681-2686
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number8
DOIs
StatePublished - Apr 15 2004

Fingerprint

Telomerase
Adjuvant Chemotherapy
Carcinoma
Gynecologic Surgical Procedures
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy. / Nouriani, Mory; Bahador, Afshin; Berek, Jonathan S.; Cheng, Joan P.; Chi, Dennis S.; Cliby, William Arthur; Del Priore, Giuseppe; Dodson, Mark K.; Duggan, Bridgette D.; Gershenson, David M.; Lentz, Scott E.; Penson, Richard T.; Robinson, William R.; Rodriguez, Mildred; Roman, Lynda D.; Yu, Mimi C.; Zempolich, Karen; Dubeau, Louis.

In: Clinical Cancer Research, Vol. 10, No. 8, 15.04.2004, p. 2681-2686.

Research output: Contribution to journalArticle

Nouriani, M, Bahador, A, Berek, JS, Cheng, JP, Chi, DS, Cliby, WA, Del Priore, G, Dodson, MK, Duggan, BD, Gershenson, DM, Lentz, SE, Penson, RT, Robinson, WR, Rodriguez, M, Roman, LD, Yu, MC, Zempolich, K & Dubeau, L 2004, 'Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy', Clinical Cancer Research, vol. 10, no. 8, pp. 2681-2686. https://doi.org/10.1158/1078-0432.CCR-0523-03
Nouriani, Mory ; Bahador, Afshin ; Berek, Jonathan S. ; Cheng, Joan P. ; Chi, Dennis S. ; Cliby, William Arthur ; Del Priore, Giuseppe ; Dodson, Mark K. ; Duggan, Bridgette D. ; Gershenson, David M. ; Lentz, Scott E. ; Penson, Richard T. ; Robinson, William R. ; Rodriguez, Mildred ; Roman, Lynda D. ; Yu, Mimi C. ; Zempolich, Karen ; Dubeau, Louis. / Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 8. pp. 2681-2686.
@article{939577cdd60f459498139fab3ab29d66,
title = "Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy",
abstract = "Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82{\%}) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53{\%}) had positive second-look procedures, whereas 66 (66{\%}) tested positive for telomerase. Twenty-nine of the 47 patients (62{\%}) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70{\%}) tested positive for telomerase. None of the 100 controls (0{\%}) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.",
author = "Mory Nouriani and Afshin Bahador and Berek, {Jonathan S.} and Cheng, {Joan P.} and Chi, {Dennis S.} and Cliby, {William Arthur} and {Del Priore}, Giuseppe and Dodson, {Mark K.} and Duggan, {Bridgette D.} and Gershenson, {David M.} and Lentz, {Scott E.} and Penson, {Richard T.} and Robinson, {William R.} and Mildred Rodriguez and Roman, {Lynda D.} and Yu, {Mimi C.} and Karen Zempolich and Louis Dubeau",
year = "2004",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-0523-03",
language = "English (US)",
volume = "10",
pages = "2681--2686",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

AU - Nouriani, Mory

AU - Bahador, Afshin

AU - Berek, Jonathan S.

AU - Cheng, Joan P.

AU - Chi, Dennis S.

AU - Cliby, William Arthur

AU - Del Priore, Giuseppe

AU - Dodson, Mark K.

AU - Duggan, Bridgette D.

AU - Gershenson, David M.

AU - Lentz, Scott E.

AU - Penson, Richard T.

AU - Robinson, William R.

AU - Rodriguez, Mildred

AU - Roman, Lynda D.

AU - Yu, Mimi C.

AU - Zempolich, Karen

AU - Dubeau, Louis

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

AB - Purpose: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

UR - http://www.scopus.com/inward/record.url?scp=11144356835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144356835&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0523-03

DO - 10.1158/1078-0432.CCR-0523-03

M3 - Article

C2 - 15102671

AN - SCOPUS:11144356835

VL - 10

SP - 2681

EP - 2686

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -